Primary orthostatic hypotension

Summary

Primary orthostatic hypotension (MONDO:0015914) is a disease and 16 clinical trials. Top therapeutic interventions include atomoxetine, droxidopa, and midodrine. A subtype of nervous system disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 16

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	primary orthostatic hypotension
Mondo ID	MONDO:0015914
Orphanet	182058
UMLS	C5680599
MedGen	1842969
Is cancer (heuristic)	no

Also known as: neurogenic orthostatic hypotension

Disease family

This is a subtype of nervous system disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › primary orthostatic hypotension

Related subtypes (71): congenital nervous system disorder, central nervous system disorder, autoimmune disorder of the nervous system, cranial nerve neuropathy, peripheral nervous system disorder, neuronitis, diplegia of upper limb, retinal disorder, developmental disability, restless legs syndrome, movement disorder, toxic encephalopathy, Barre-Lieou syndrome, Gerstmann syndrome, drug-induced akathisia, drug-induced dyskinesia, stiff-person syndrome, Worster-Drought syndrome, corneal-cerebellar syndrome, pachygyria-intellectual disability-epilepsy syndrome, porencephaly-cerebellar hypoplasia-internal malformations syndrome, symmetrical thalamic calcifications, neonatal brainstem dysfunction, rippling muscle disease with myasthenia gravis, periodic paralysis, qualitative or quantitative protein defects in neuromuscular diseases, specific learning disability, cerebellar hypoplasia-tapetoretinal degeneration syndrome, locked-in syndrome, dopa-responsive dystonia, idiopathic recurrent stupor, chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids, spontaneous periodic hypothermia, Sydenham chorea, duplication of the pituitary gland, Balint syndrome, paraneoplastic neurologic syndrome, persistent idiopathic facial pain, serotonin syndrome, hypothalamic adipsic hypernatraemia syndrome, exercise-induced malignant hyperthermia, perineural cyst, neuromuscular disease, neuromyelitis optica, AL amyloidosis, AA amyloidosis, neuroleptic malignant syndrome, infectious disorder of the nervous system, central nervous system malformation, synaptopathy, nervous system neoplasm, sensory ganglionopathy, radiculitis, wet beriberi, perceptual disorders, prepubertal anorexia nervosa, neurocutaneous syndrome, neurovascular disorder, Wallerian degeneration, nervous system injury, neurosarcoidosis, neuroendocrine disorder, tubulinopathy, atactic disorder, hereditary neurological disease, meningitis-retention syndrome, KIF1A related neurological disorder, neurological pain disorder, neurodevelopmental disorder, post 5-alpha-reductase inhibitors treatment syndrome, post-selective serotonin reuptake inhibitor sexual dysfunction

Subtypes (2): peripheral motor neuropathy-dysautonomia syndrome, inherited orthostatic hypotension

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 16.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	6
PHASE2	4
PHASE4	3
PHASE3	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03229174	PHASE4	COMPLETED	Brain Perfusion & Oxygenation in Parkinson’s Disease With NOH
NCT03350659	PHASE4	COMPLETED	Efficacy and Safety of Midodrine and Atomoxetine for Neurogenic OH
NCT04128137	PHASE4	UNKNOWN	Efficacy and Tolerance of Flucortac in Patients With Orthostatic Neurogenic Hypotension
NCT00738062	PHASE3	COMPLETED	Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
NCT01132326	PHASE3	COMPLETED	Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304)
NCT07089043	PHASE2	RECRUITING	A Study in Subjects With Neurogenic Orthostatic Hypotension
NCT00977171	PHASE2	TERMINATED	Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome
NCT02705755	PHASE2	COMPLETED	TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
NCT02784535	PHASE2	COMPLETED	Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)
NCT04620382	EARLY_PHASE1	COMPLETED	Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients
NCT01799915	Not specified	RECRUITING	Natural History Study of Synucleinopathies
NCT05295810	Not specified	RECRUITING	Hypercapnia in Orthostatic Hypotension
NCT05489575	Not specified	RECRUITING	CPAP for the Treatment of Supine Hypertension
NCT05908760	Not specified	RECRUITING	CO2 Rebreathing in nOH: A Proof-of-Concept Pilot Study
NCT06751888	Not specified	NOT_YET_RECRUITING	Controlled CO2 Inhalation in NOH
NCT04976101	Not specified	WITHDRAWN	Sinusoidal Galvanic Vestibular Stimulation for Neurogenic Orthostatic Hypotension / Syncope

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ATOMOXETINE	4	6
DROXIDOPA	4	4
MIDODRINE	4	2
FLUDROCORTISONE ACETATE	4	1
AMPRELOXETINE	3	1
FLUDROCORTISONE	2	1
CHEMBL1593851	0	4
CHEMBL4740452	0	1